Support the FDA Modernization Act 3.0

Support the FDA Modernization Act 3.0

Name of Bill: FDA Modernization Act 3.0 

Bill Number: H.R. 7248 

FDA Modernization Act 3.0In December 2022, President Biden signed into law the FDA Modernization Act 2.0 (FDAMA 2.0) to eliminate an animal-testing mandate for drug manufacturers. The new law was celebrated across the country by animal activists and advocates for promoting the use of more predictive drug testing methods. Alas, the FDA has not taken steps to update its regulations, which still require animal testing and are now in conflict with the law. 

The FDA Modernization Act 3.0 (FDAMA 3.0) will push the FDA to do its job by requiring the agency to publish a final rule implementing FDAMA 2.0. This rule would have to include the establishment of a qualification process for non-animal testing methods so that drug companies know what methods, other than animals, are available for testing the safety and efficacy of their drugs.

While it is frustrating that the FDA has not taken steps to implement FDAMA 2.0, there are steps we can take to hold them accountable, starting with passage of FDAMA 3.0.

Calls to Action: 

  1. Please contact your U.S. representative and urge them to cosponsor this bill.
  2. Spread the word! Share this page with your social network.



  • Your Representative


*Required fields

If you take action and have not already registered, you will receive periodic updates and communications from National Anti-Vivisection Society.


Please Cosponsor the FDA Modernization Act 3.0

Dear [Decision Maker],

I am writing to you today as a voting constituent of your district to urge you to cosponsor the bipartisan FDA Modernization Act 3.0.

In December 2022, FDA Modernization Act 2.0 was signed into law to eliminate the animal testing requirement for new drugs. Unfortunately, the FDA has failed to finalize rules for implementation, so regulations and guidance are not consistent with the updated law.

The FDA Modernization Act 3.0 will require the FDA to publish a final rule implementing the 2.0 version. It would also mandate that the Department of Health and Human Services establish processes and transparency factors for new drug testing methods.

Removing the animal testing requirement for new drugs will empower researchers to employ less harmful non-animal methods for drug testing, such as cell-based assays, organ chips, computer modeling, and bioprinting. When applicable, these human cell-based methods can yield more reliable scientific results at significantly less cost, and in less time, than traditional animal tests.

Please stand with your colleagues and cosponsor the FDA Modernization Act 3.0!

Thank you for your time and attention.

[Your Name]
[Your Address]
[City, State ZIP]